Closed Loop Medicine secures Seed Round from Cambridge Angels
New Cambridge start-up leveraging the expertise and science at the interface of the digital technology and life sciences sectors.
Closed Loop Medicine (CLM), the Cambridge-based health tech startup that helps doctors and healthcare providers to deliver personalised treatment regimens for patients, has raised 150,000 SEIS from some of the city’s leading angels and other local investors.
Closed Loop Medicine (CLM) is a new breed of therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised regimens. The company combines proven drugs with digital therapeutics enabling the digitisation and data capture of an entire care continuum. Digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used independently or in concert with medications, devices, or other therapies to optimize patient care and health outcomes.
CLM is developing these new combined therapies in chosen therapeutic areas, and intends to work with pharmaceutical companies in enhancing their therapies in selected care pathways.
—
“A key driver in the future of medicine is the ability to gather longitudinal data on an individual patient and use that to improve and individualise treatment and dosing regimens through a closed loop feedback approach.”
Dr Andy Richards
—
The company is chaired by Dr Andy Richards CBE, one of the UK’s most distinguished life sciences entrepreneurs. Dr Richards is also a Director of Ieso Digital Health, chairman of Arecor, Congenica, Abcodia, the Babraham Research Campus and a founder member of the Cambridge Angels.
Alongside Dr Richards, CLM’s co-founders are a world-class team pharmaceutical and healthcare innovators as well as technology specialists. They have created a cutting-edge company which is at the interface of the Cambridge clusters expertise in technology and life sciences.
Dr Paul Goldsmith, co-founder said: “Andy and I have already worked together to build a drug company and a digital health company. It is exciting now to be doing the combination of drugs+digital, together with a stellar cast of co-founders. We’re also joined by incredibly talented investors from the life sciences and technology sectors who we know from experience will provide that added value so critical to our success.”
Vishal Gulati, one of the UK’s top life science and digital health entrepreneurs, and an investor in Closed Loop Medicine, said: “the true potential of digital technologies in healthcare will not be realised until we are able to integrate them into drug development in a way that the combined best of both can become the new standard. Closed Loop’s team understands all the elements of this and should be able to develop new and exciting products. This is an exciting prospect.”
Dr Richards added: “A key driver in the future of medicine is the ability to gather longitudinal data on an individual patient and use that to improve and individualise treatment and dosing regimens through a closed loop feedback approach.”
“The insights gathered from doing this hundreds and thousands of times with the application of AI technologies will accelerate this process. The Closed Loop Medicine approach will impact on many therapeutic pathways to improve outcomes for patients, as well as developing our own products we expect to partner with pharmaceutical companies to achieve these aims.”
About Closed Loop Medicine
Closed Loop Medicine is a Cambridge-based therapeutics company focused on care pathways, outcomes and the provision of dynamic personalised regimens. CLM has a development pipeline that integrates Drug + Digital+ Device for the treatment of some of the biggest challenges facing global health systems. For now, CLM is working on treating sleep disorders and hypertension but in the future will be working on other health problems.
By focusing on individual care pathways, CLM can augment proven drugs with digital therapeutics enabling the digitisation and data capture of an entire care continuum for dynamic personalised regimens. Digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease.
The founders of CLM have a track record of working together and between them have launched many highly successful commercial enterprises including drugs, digital health, diagnostics and devices. The team has full experience of technology development through to market access, reimbursement and uptake.
CLM was founded in 2017. Its HQ is in London, UK.